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ABSTRACT
We have studied the binding of neomycin to a 171mer
RNA (ψ-RNA) from the packaging region of the LAI
strain of human immunodeficiency virus type-1, HIV-1
(LAI). The RNase I footprinting studies reveal that the
primary binding site for the drug is in stem–loop 1,
which contains the dimer initiation site of HIV-1.
Loading this site with neomycin causes a structural
change in the RNA, allowing nucleotides in the neighboring stem–loop 2 to participate in the drug site.
Drug binding to secondary sites induces structural
changes in other stem–loops of the RNA. Footprinting plots, showing cutting at a site as a function
of drug concentration, were analyzed using a two-state
model to obtain relative site-specific binding
constants. Circular dichroism measurements show
that neomycin binding to ψ-RNA changes the intensity
of the strong negative CD band at 208 nm, confirming
that neomycin induces structural changes. Melting
studies of the RNA showed melting transitions in the
absence of drug at 28.2, 37.2, 47.4, 55.5 and 60.8°C.
Only the first two were affected by drug binding, the
reason for this being explained by our analysis.
INTRODUCTION
The possibility of targeting RNA with drugs as a means of
controlling viral infections is gaining considerable attention
(1–5). Similarly to proteins, large RNA molecules fold into
complex structures providing unique binding surfaces for
drugs. Since RNA function often depends on folding and the
folded structure of RNA depends on sequence, it may be
possible to design agents that control RNA function by
targeting specific RNA structures.
The aminoglycosides are drugs which bind to RNA (4,5).
Interest in these agents stems from their well-known antibacterial
effects, which they exert by binding to the A-site on rRNA and
blocking protein synthesis. Since the aminoglycosides can
easily change their shape, they can bind to a variety of different
RNA sites. While much has been learned about aminoglycosides interacting with small RNA molecules (6–16), less is

known about their ability to bind to and change the structure of
large RNA targets.•
Earlier, we outlined the theory and experimental procedures
for obtaining binding constants from aminoglycoside–RNA
footprinting data (17,18) and absorption measurements (19).
We studied a segment of RNA from the packaging region or ψ
element of HIV-1 (strain LAI) (Fig. 1A) (20). Since this region
of RNA is important in a number of steps in the life cycle of the
virus (21), it is a potential target for AIDS-directed drugs. In
this report we have studied binding of the aminoglycoside drug
neomycin B (Fig. 1B) to the ψ-RNA, using quantitative RNase I
footprinting, circular dichroism (CD) and UV melting techniques.
MATERIALS AND METHODS
Footprinting
The RNA was synthesized using template DNA and T7 RNA
polymerase in the presence of the four ribonucleotide triphosphates and, after purification, was 5′-end-labeled with 32P
(17,18). Analysis revealed that although a 176mer was
targeted, a pentamer in the DNA template was not transcribed.
The ψ-RNA is a 171mer, missing the sequence 5′-AAAUU at
positions 303–307 of the HIV (LAI) genome. This is reflected
in the indexing shown in Figure 1A.
The footprinting experiments were carried out in a total
volume of 10 µl in 10 mM Tris–HCl pH 7 buffer (17,18). The
enzyme RNase I was chosen over other enzymes and chemical
cleavage agents because it cuts at many sites in the RNA and
exhibits reproducible cleavage characteristics, essential for
quantitative studies. The footprinting solutions were made
by adding a small amount of radiolabeled RNA (∼0.05 µM)
to 1.1 µM unlabeled RNA (ε260 = 1.2 × 106 M–1 cm–1), adding
drug, waiting 30 min for equilibration and adding 1 µl of the
enzyme (0.04 U). The cutting reactions, conducted at room
temperature (∼21°C), were stopped by addition of 5 µl of 8
M urea (National Diagnostics) loading buffer. Prior to denaturing PAGE, samples were heated to 95°C for 5 min and
immediately placed on ice. A 9% gel allowed for separation
of the smaller (<100 nt), fast migrating oligonucleotides,
whereas a 6% gel was used to resolve the larger oligomers
(>100 nt). Binding/enhancement events could be detected in
the region from 230 to ∼380 of the RNA. After electrophoresis, the radioactive fragments were detected by autoradiography and the resulting photographic film (Figs 2 and 3)
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Figure 1. (A) The proposed structure of the ψ-RNA. It includes: a main stem,
formed by HIV-1 (LAI) coding sequences, flanking SL 1 and SL 4; SL 1,
which contains the dimer initiation site, 5′-GCGCGC; SL 2, which has the 5′
splice donor site of HIV; SL 3, SL 4 and the start codon of the gag gene at positions
236–238. The circles indicate nucleotides that are involved in binding neomycin,
i.e. exhibit type 1 footprinting plots. The triangles indicate nucleotides that
exhibit structural changes (enhancements) in the presence of neomycin, i.e. type 2
or type 3 footprinting plots. (B) The structure of neomycin B.

scanned to obtain spot intensities (17,18). The intensities were
corrected for cutting and loading errors for each lane (<15%)
and control lane intensities were subtracted. The resulting
intensities, plotted versus drug concentration for each RNase I
cutting site on the 171mer, yield the footprinting plots. Some
are shown in Figure 4 and all are summarized in Table 1. They
were analyzed as described below.
Circular dichroism
The CD spectra were collected at room temperature (21 ± 0.2°C)
using an Aviv model 202 CD instrument. Scans were from 300
to 200 nm with a resolution of 1 nm, with data sampling every
2 s. The 1 cm cell contained 250 µl of a 0.5 µM solution of the
RNA in 10 mM Tris–HCl pH 7 buffer. Control experiments
showed that the spectroscopic changes occurred within the
time of mixing after addition of the drug. The final neomycin
concentrations for the solutions were 0, 1.4, 2.8, 5.6, 8.4, 11.2,
14.0, 16.7, 19.4, 22.1, 24.8, 27.5 and 32.8 µM. The spectra
were corrected for dilution, which was <10% at the end of the
titration. The value of ∆ε, in M–1 cm–1 nucleotide–1, was calculated

Figure 2. Footprinting autoradiogram (6% polyacrylamide gel) of neomycin B
and ψ-RNA using RNase I as the cleavage agent. Lane 1, RNA alone; lane 2,
base hydrolysis ladder; lane 3, a G ladder generated using RNase T1. Other
lanes contain neomycin B concentrations (µ M) as follows: lane 4, 0; lane 5, 1;
lane 6, 2; lane 7, 3; lane 8, 4; lane 9, 5; lane 10, 6; lane 11, 7; lane 12, 8;
lane 13, 9; lane 14, 10; lane 15, 11; lane 16, 12; lane 17, 13; lane 18, 14; lane 19,
15; lane 20, 16; lane 21, 17; lane 22, 18; lane 23, 20; lane 24, 25. The black
bars on the right show approximate locations of the loops for SL 1 (bottom),
SL 2, SL 3 and SL 4 (top).

using ∆ε = ψ/(32.98)(171)lM, where ψ is the observed ellipticity
in degrees, l is the path length and M is the concentration of the
RNA in mol l–1. Neomycin itself does not exhibit a CD spectrum
in the wavelength range studied. The CD spectra of the ψ-RNA
in the presence of various amounts of neomycin are shown in
Figure 5 and CD as a function of drug concentration for
selected wavelengths is shown in Figure 6.
UV melting studies
The UV melting data were obtained using a Beckman Coulter
DU 640 spectrophotometer at 260 nm. The melting studies
were carried out in the temperature range 20–80°C using a scan
rate of 0.2°C min–1. Samples were prepared by briefly degassing
520 µl of the 10 mM Tris–HCl pH 7 buffer using a vacuum,
adding 1.7 µl of a stock RNA solution and mixing using a
micropipette. A 250 µl aliquot was transferred into each of two
1 cm path length cells and the concentration of RNA (0.5 µM)
determined optically. After addition of a small amount of a
stock solution of the drug (neomycin does not absorb at 260 nm)
and mixing with a micropipette, the solution was equilibrated
for 20 min prior to carrying out the melting experiment. The
values of [drug]/[RNA] were 0, 0.20, 0.25, 0.36, 0.50, 0.68,
0.75 and 1.0. After correcting the absorbance data for dilution
due to addition of the drug (<2%), the first derivative of
absorbance with respect to temperature, dA/dT, was calculated
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Figure 3. Footprinting autoradiogram (9% polyacrylamide gel) of neomycin B
and ψ-RNA using RNase I as the cleavage agent. Lane 1, RNA alone; lane 2,
base hydrolysis ladder; lane 3, a G ladder generated using RNase T1. Other
lanes contain neomycin B concentrations (µM) as follows: lane 4, 0; lane 5, 1;
lane 6, 2; lane 7, 3; lane 8, 4; lane 9, 5; lane 10, 6; lane 11, 7; lane 12, 8; lane 13,
10; lane 14, 12; lane 15, 14. Black bars on the right identify the loop regions of
SL 1 (bottom), SL 2, SL 3 and SL 4 (top).

using Lagrange interpolation. Three plots of dA/dT are shown
in Figure 7. Each plot was fitted to a sum of Gaussians using
Peak Fit 4 (Jandel Scientific). The melting temperatures were
the positions of these peaks.
RNA secondary structure prediction
A prediction of the secondary structure of the ψ-RNA was
obtained using the Mfold v.3.0 algorithm offered at http://
bioinfo.math.rpi.edu (22). Folding was done at 37°C with 1 M
NaCl, specifying that the regions between stem–loop 3 (SL 3)
and SL 4, and SL 4 and the main stem, be single stranded. These
constraints are consistent with the cutting pattern of RNase I in
these regions. The lowest energy structure found using Mfold
(see Fig. 1A) has the four major features, SL 1 to SL 4, found
by Clever et al. (20) and Zeffman et al. (23) in the packaging
region. The presence of SL 1 to SL 4 in the ψ-RNA is consistent
with cutting by RNase T1 at the guanine sites in the loops (18).
Cutting by RNase T1 in the loop of SL 1 (see Figs 2 and 3)
indicates that the loop is single stranded and that the RNA is
monomeric. The monomeric form of ψ-RNA is consistent with
our earlier work on monomer/dimer equilibria of HIV
sequences (24). The work of Muriaux et al. (25) also showed
that, under the conditions of our footprinting studies, long
RNA transcripts from the packaging region are monomeric.
Furthermore, a transcript related to ψ-RNA (156mer) was
found to be monomeric under the conditions of our footprinting experiments (A. Paoletti, personal communication).

Figure 4. Selected footprinting plots (spot intensity versus µM drug concentration)
of neomycin B interacting with ψ-RNA using RNase I as the cleavage agent.
The site numbers refer to Figure 1A.

Since the footprinting and CD studies in this report were
done at a different temperature (21°C) and ionic strength (10 mM
Tris–HCl pH 7) from those employed in the folding program
Mfold (22), the true secondary structure of the ψ-RNA is
unknown. The structure in Figure 1A should be considered a
‘working model’ on which binding/structural information for
neomycin are summarized.
RESULTS
Footprinting
Some of the footprinting plots obtained from the 6% and 9%
gels are shown in Figure 4. The behavior of each of the plots is
summarized in Table 1. It is clear that the primary binding site
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Table 1. Summary of footprinting plot behaviors
From 9% gel

From 6% gel

Site

Typea

Site

Typea

235A

4

236C

4

237G

4

238C

4

239A

3

240G

3

241G

1

241G

1c

242A

1

242A

1c

243C

1

243C

1c

244U

1

244U

1c

245C

1

245C

1c

248C

1

248C

1c

249U

1

249U

1c

254G

3

254G

3

255A

3

255A

3

257G

3

262C

1

262C

1d

267C

1

267C

1d

268A

1

268A

1d

269A

1

269A

1d

271A

3

271A

3

282G

3b

282G

2

283G

2

285G

1e, 2

297C

2

298G

2

299C

2

300C

2

301A

2

302A

2

309U

2

310G

2

330A

1f

332A

1f

336A–337U

1f

338–340G

4

351U

3

352C

3

354G

3

aType 1 plots show intensity decreasing with drug concentration. Type 2 plots
show intensity increasing with drug concentration to a maximum, followed by
a decrease. Type 3 plots show intensity increasing with drug concentration for
the entire range investigated. Type 4 plots show no systematic change in
intensity with drug concentration.
bThis may in fact be type 2, as found for the 6% gel, but the 9% gel does not
go to as high a drug concentration as does the 6% gel.
cK = 2.7 × 105 M–1.
dK = 4.5 × 105 M–1.
eK = 5.6 × 105 M–1.
fK = 1.2 × 105 M–1.

Figure 5. CD spectra of ψ-RNA in the presence of neomycin B. The quantity
∆ε has units of M–1 cm–1 nucleotide–1.

Figure 6. Plots showing ∆ε (M–1 cm–1 nucleotide–1) as a function of neomycin
concentration at different wavelengths. Lines are best fits to the two-state
model using a single K for all wavelengths.

for neomycin is mostly located in the loop and stem region of
SL 1. Four nucleotides in this region, C 262, C267, A268 and A269,
exhibit decreased cutting as drug is added to the system (type 1
behavior). A site in SL 2, G 285, also exhibits type 1 behavior.
Secondary binding sites, with lower values of K, affect nucleotides
G241, A242, C243, U244, C245, C248, U249, A 330, A332, A336 and U337.
The latter are mainly located in the linker region between the
main stem and SL 1 and in the region between SL 3 and SL 4
(Fig. 1A).
Apparent binding constants for these sites were calculated
using the previously described two-state model (18), which
assumes that only a single site binds the drug. This is the case
for the primary binding site. For a secondary site, the total drug
concentration in the model should be reduced by the amount of
drug already bound to stronger sites, i.e. by the RNA concentration; the correction is small. For the sites G241–U249, grouped
together, the model yielded K = 2.7 × 10 5 M–1; for the sites
C262–A269, grouped together, it yielded K = 4.5 × 10 5 M–1
(primary binding site). Site G285 gave K = 5.6 × 10 5 M–1 and the
sites A 330–U337, grouped together, yielded K = 1.2 × 10 5 M–1.
The relative uncertainty in each K, estimated as the change
which increases the deviation of calculated from experimental
intensities by 10%, is about one-third.
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Table 2. Melting transitions for ψ-RNA in the presence of neomycin
r valuea

T1

T2

T3

T4

T5

0.0b

28.2 ± 0.8

37.2 ± 1.8

47.4 ± 1.0

55.5 ± 1.4

60.8 ± 1.2

0.20

29.0

40.6

47.6

54.8

60.6

0.25

30.8

40.6

47.4

56.2

65.2

0.36

32.4

38.8

46.5

52.8

60.0

0.50

31.9

40.1

47.7

53.4

59.0

0.68

32.2

38.5

50.4

54.2

60.2

0.75

28.7

36.0

48.6

53.6

59.7

1.00

30.6

36.3

48.8

55.1

61.0

ar

is the ratio of drug concentration to RNA concentration.
and standard deviation of four runs.

bAverage

Figure 7. Representative first derivative melting curves, dA/dT, for ψ-RNA in
the absence and presence of neomycin B (r = [neomycin]/[RNA]). A is absorbance
at 260 nm. Each is a least squares fit to a sum of Gaussian peaks. For the r = 0
curve, the peaks are centered at 28.2, 37.2, 47.4, 55.5 and 60.8°C. Peak centers
for the other curves are in Table 2.

Binding of neomycin to ψ-RNA produces two kinds of
enhancement footprinting plots. Nucleotides that exhibit type 2
plots (cutting intensity increases with drug concentration to a
maximum, followed by a decrease) are G282, G283, C297, G 298,
C299, C300, A301, A302, U309 and G310. These sites, located in the
lower stem portion of SL 2 and in the region between SL 2 and
SL 3, experience a structural change as the highest affinity site
in the stem of SL 1 binds neomycin. Sites that exhibit type 3
footprinting plots (intensity increases with drug concentration
for the entire range investigated) are A 239, G240, G 254, A255, G257,
A271, U351, C352 and G354. They are in the ‘linker’ between the
main stem and SL 1, in the loop and stem of SL 1 and near SL 4.
For all the type 3 sites, the increase in cutting is small at low
drug concentration, indicating that they experience little
change in structure while the highest affinity site in SL 1 is
loading drug. However, cutting at these sites increases more
rapidly with drug concentrations >9 µM, indicating that later
drug binding events cause these nucleotides to undergo a structural change. In this range of drug concentration, the type 2
sites in SL 2 exhibit decreased cutting. Site G285 exhibits
unusual behavior (Fig. 4). At low drug concentration it exhibits
strong binding (K = 5.6 × 105 M –1), but at higher drug concentration, cutting at the site increases and finally decreases. This
nucleotide appears to be involved in the high affinity drug site
in the stem of SL 1, but drug binding to a secondary site may
cause a structural change which makes G285 accessible to
cleavage by RNase I. Some nucleotides (A235, C236, G237, C238
and G338–340), in the main stem and near SL 4, show no change
in RNase I cutting intensity with neomycin concentration.
Circular dichroism
CD spectra of the ψ-RNA in the presence of neomycin are
shown in Figure 5. The spectrum of the RNA is A-form (26),
with a strong positive band at 266 nm, a strong negative band
at 208 nm and a weaker negative band at ∼240 nm. Neomycin
in the concentration range 0–14 µM intensifies the band at
208 nm. We fitted CD intensities for 17 wavelengths in the
region 204–220 nm and drug concentrations 0, 1.4, 2.8, 5.1,

8.4, 11.2 and 14 µM to a two-state binding model, assuming a
single value of K. The best fit was obtained for K = 4.4 × 105 M–1.
The CD changes at high drug concentration (loss of band intensity) were not analyzed. Unlike the case of paromomycin (18),
CD does not show evidence for a stronger neomycin binding
event at low drug concentration.
UV melting studies
Figure 7 shows melting profiles (dA/dT) for RNA alone and
RNA with two different neomycin concentrations. Temperatures of melting transitions were obtained from fits of dA/dT to
a sum of Gaussians. For RNA alone, four determinations were
made. All showed a strong melting transition at 47.4 ± 1.0°C
(T3) and four weaker transitions at 28.2 ± 0.8°C (T1), 37.2 ±
1.8°C (T2), 55.5 ± 1.4°C (T4) and 60.8 ± 1.2°C (T5). Table 2
shows melting temperatures for various r = [drug]/[RNA].
Errors are probably ∼1°C. It is seen that T1 increases with r,
leveling off at ∼31°C for r ≈ 0.3. The second temperature T2
increases with r more rapidly than T1, leveling off at ∼40°C for
r ≈ 0.2. The temperatures of the other three transitions are not
much changed by added neomycin.
DISCUSSION
Three experimental techniques have been employed to study
the binding of neomycin B to the packaging region of HIV-1.
Each gives somewhat different information about the effects of
binding. Footprinting is the only technique capable of
revealing the location of drug binding on the ψ-RNA.
From the type 1 footprinting plots (decreased cutting with
increased drug concentration), nucleotides at positions 241–249,
262–269, 330–337 and 285 are blocked by neomycin binding.
By fitting a two-state model to the footprinting plots for each
region, site-specific drug binding constants may be determined.
For the three regions and 285 we found K = 2.7 × 105, 4.5 × 105,
1.2 × 105 and 5.6 × 105 M –1, respectively.
If there is competition between neomycin and RNase I for a
site, the binding constants derived from footprinting data will
be lower than the true values. Evidence for competition is that
the values of K obtained from the footprinting experiments are
much lower than those obtained for neomycin interacting with
small RNA constructs (27,28). While it may be argued that the
differences in K are due to the different RNA targets used, the
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footprinting-derived binding constant of paromomycin toward
Ψ-RNA is also lower than its true value (18), obtained using
CD and absorption, by more than an order of magnitude. As
expected, the largest binding constant for neomycin is higher,
by a factor of three, than the largest K for paromomycin. This
is probably related to the fact that of the two drugs, neomycin
has the greater positive charge (27,28).
Interestingly, the primary binding site for neomycin, at
nucleotides 262–269 in the stem of SL 1 and at 285 in SL 2, is
a secondary binding site for paromomycin (18). Since the only
difference between the two drugs is the group on the 6′ position
of ring I (Fig. 1B) (for neomycin, an amino group; for paromomycin, a hydroxyl), the difference in specificity between the
drugs is surprising. It is strongly suggested that ring I of the
drug faces towards RNA (6–8,10) and not into the solvent, as
is the case for neomycin bound to the tau exon 10 splicing
regulatory element (9). The diversity of interaction sequences
and bound drug conformations for the aminoglycosides (6–10)
make it impossible to speculate on the structure of the neomycin–
ψ-RNA complex based on footprinting data.
Type 2 footprinting plots, for which cutting increases with
drug concentration, reaches a maximum and decreases (Fig. 4),
are common with neomycin. The increase appears to be due to
a structural change in the RNA induced by drug binding at a
location other than that being observed. The subsequent
decrease may be due to another structural change caused by
drug binding to a secondary site or to drug binding at the
observed site. As noted below, the former is more likely for
neomycin binding to the ψ-RNA. The structural change
causing increased cleavage, by making nucleotides in SL 2
more accessible, occurs over the range of drug concentrations
for which the highest affinity site binds drug. While this site
involves nucleotides in SL 1, G285 or the nearby looped-out
nucleotide A296 may also be involved. As shown in Figure 4,
G285 exhibits a sharp decrease in cutting while C262, C267, A268
and A 269 exhibit strong decreases, indicating that part of SL 2
is involved in the primary site. As these sites bind drug, nucleotides in the lower stem region of SL 2 and between SL 2 and
SL 3 undergo a structural change. The change may be caused
by G 285 moving to the drug site in SL 1. Interestingly, in the
drug concentration range 6–12 µM cutting at G285 increases
(Fig. 4), indicating that loading secondary sites with neomycin
makes G 285 accessible to cleavage by RNase I.
Structural changes similar to those observed with ψ-RNA,
but on a smaller scale, occur with neomycin interacting with a
small RNA aptamer (8). In the neomycin–aptamer complex the
drug is encapsulated in a binding pocket by a looped-out RNA
base, which serves as a cap to anchor the drug in place. Binding of
neomycin to the aptamer causes part of the RNA to rearrange to
form a cap for the drug. Interestingly, we see little structural
change for nucleotides near the primary site (G254, A255, G257
and A271) or for those farther away in sequence (A239, G240,
U351, C352 and G354) when the primary site is loading with drug.
These nucleotides give type 3 footprinting plots with a modest
increase in cutting for low drug concentrations. For drug
concentrations for which the secondary sites bind neomycin,
the nucleotides in the stem of SL 2 and sites having type 3 plots
undergo additional structural change.
The CD studies were undertaken to verify the existence of
drug-induced structural changes in RNA. The ψ-RNA shows a
CD spectrum which is A-form (26), having a strong positive

band near 266 nm and a weaker negative band near 240 nm.
The addition of drug, up to ∼14 µM concentration, causes the
former to strengthen and the latter to weaken, indicating a
structural change in the RNA. For concentrations >14 µM, the
changes reverse and overall band intensity decreases. These
effects may be due to additional drug binding or to loss of RNA
from solution by precipitation, and were not analyzed quantitatively.
CD intensities for 17 wavelengths between 204 and 220 nm
and seven drug concentrations between 0 and 14 µM were
fitted to a two-state binding model. Assuming that the CD at all
wavelengths responded to the same binding event, the value of
K was found to be 4.3 × 105 M –1. Since this is an average for the
binding events that occur over this concentration range (three
such events were found in the footprinting experiments), K for
the highest affinity site must exceed 4.3 × 10 5 M–1.
Plots of CD intensity versus neomycin concentration DT for
each wavelength seem smooth and monotonic for DT < 14 µM.
In contrast, similar plots for paromomycin (18) show CD
intensities changing very rapidly with DT < 2 µM, indicating a
distinct binding event with a large value of K.
Melting studies should also give information about drug
binding (29). Let ∆Hj and ∆Sj be the enthalpy and entropy
differences between the melted and unmelted domain j, giving
the domain a melting temperature of Tj = ∆Hj/∆Sj. Since A, the
absorbance at 260 nm, increases most rapidly with temperature
(T) near a Tj, the first derivative dA/dT has a maximum at each
Tj. As shown in Figure 7, the ψ-RNA exhibits five melting
transitions between 25 and 75°C.
Neomycin binding to the unmelted domain j increases its
entropy and/or decreases its enthalpy. Since the melted domain
(single stranded) binds drug poorly, Tj is increased by drug
binding. The observed dA/dT curve is the weighted average of
curves for RNA with and without bound drug. The fraction of
RNA molecules with drug bound at domain j increases with
free drug concentration, DF, and the binding constant for the
domain, Kj (which depends on temperature). Thus increasing DF
should increase Tj, as observed for the lowest melting transition,
T1, for ψ-RNA (Table 2).
The interpretation of the effect of neomycin on subsequent
melting transitions is more complicated because of the way the
melting experiment was conducted. Raising the temperature
above T1 causes domain 1 to melt, losing the bound drug, but
also decreases K1. Detailed model calculations show that the
melting temperature increases with drug concentration but,
because of the decrease in K1, T1 levels off when only a small
fraction of domains 1 have drug bound. When domain 1 loses
drug, DF increases, increasing drug binding to other domains of
the RNA. This may be the reason why T2 increases more
rapidly with drug concentration than does T1. Since raising the
temperature decreases all Kj, there may be no drug bound to
domain j when T approaches the higher Tj. This is probably
why T3, T4 and T5 are not affected by drug concentration (Table 2).
Correlating the melting data with the footprinting results and
identifying the melting domains with the binding regions
found in footprinting will require additional study.
In summary, the footprinting experiments show that the
highest affinity neomycin site on ψ-RNA is in the stem of SL 1 at
nucleotide positions 262–269, but 285 on the neighboring stem
loop SL 2 is also part of the site. The participation of 285 in the
primary site appears to cause structural changes in the lower
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stem region of SL 2 and between SL 2 and SL 3. The largest
binding constants obtained for neomycin (from type 1 plots) were
for site G285 (K = 5.6 × 105 M–1) and for sites C262–A269 (K = 4.5 ×
10 5 M–1) but, due to competition between the drug and RNase
I, these values are lower than their true values. Binding regions
with lower values of K are associated with G241–U249, mostly in
the stem of SL 1, and A 330–U337, in the linker region between
SL 3 and SL 4. Loading these sites with drug makes 285, which
was part of the strong drug site, susceptible to cleavage by
RNase I.
The CD measurements show that ψ-RNA binds drug and
that the drug binding induces a structural change. From the
dependence of CD intensity on drug concentration (0–14 µM),
one can derive a binding constant for the relevant binding
event of 4.4 × 10 5 M–1. This is considerably smaller than the
largest K found for paromomycin from CD measurements (18).
Since neomycin is expected to bind better than paromomycin
(27,28) it is suggested that the strongest binding event for
neomycin has no effect on the CD spectrum. Similarly to the
CD measurements, the UV absorption measurements show the
effect of a strong binding event for paromomycin but not for
neomycin. Apparently, the strongest neomycin binding
event does not induce the same kind of structural change as
the corresponding event for paromomycin. As noted, the
primary binding sites for the two drugs on ψ-RNA are
different. Considering the structural similarity between the
drugs, this difference is remarkable.
For ψ-RNA in the absence of drug, five melting transitions
were observed, with melting temperatures Tj between 28 and
61°C. Drug binding raises the two lowest Ti by several degrees
(Table 2), but has no effect on the others. This is probably
because the Ki decrease with temperature, so that drug is not
bound when one reaches the higher Ti. The values of T1 and T2
level off when the drug concentration is less than one-third the
RNA concentration. This cannot be due to saturation of the
binding sites with drug; calculations show that it is a consequence of the decrease in drug binding constants with temperature.
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